Inmagene, HUTCHMED begin Phase I dosing of atopic dermatitis asset
Inmagene assumed the development responsibility of IMG-007 at the candidate stage.
Hong Kong (China SAR)
Latest in
Hong Kong (China SAR)
Provention Bio begins Phase IIa systemic lupus erythematosus trial
Provention Bio will recruit adult SLE subjects across nearly 28 centres in the US and Hong Kong for the study.
Triple drug combination shows promise in Covid-19 treatment
Early data from a small trial conducted by the University of Hong Kong has demonstrated promise for the Covid-19 treatment…
COVID-19 coronavirus: Top ten most-affected countries
One Asian country and seven European countries are among the ten most affected list of countries with coronavirus, while more…
Cocrystal Pharma to study hepatitis C drug in Hong Kong
US-based biotechnology firm Cocrystal Pharma has signed a clinical trial agreement with Humanity & Health Research Centre in Hong Kong…
M&As this week: Zymergen, Celgene Corp, China Biology Services Group Limited
Molecular technology firm Zymergen Inc has acquired Radiant Genomics Inc, a functional metagenomics research company.
Deals this week: AmpliPhi Biosciences, Argos Therapeutics, Juvenescence Limited
AmpliPhi Biosciences Corp plans to issue shares of its common stock in a public offering.